Skip to content
  • News
  • Contacts
  • Careers
    • Work with us
    • Privacy Notice
  • Investor Relations
  •  
    • Kedrion S.p.A
    • Kedrion Biopharma GmbH
    • Kedrion Biopharma – Austria
    • Kedrion Biopharma – Portugal
    • Kedrion Biopharma – Poland
    • Kedrion Biopharma – Switzerland
    • Kedrion Biopharma – Russia
    • HUMAN Bioplazma Kft
    • Kedrion Biopharma Inc.
    • Kedrion Mexicana S.A.
    • Kedrion de Colombia
    • Kedrion Betaphar
    • KEDPLASMA USA
  •  
  •  
    • LinkedIn
  • About us
    • Corporate Structure
    • Annual Report
    • Corporate Social Responsibility
      • Code of Conduct
      • Environment, Health & Safety
      • Supporting our people
      • Support to communities
  • Expertise
    • Activities
    • Medical & Scientific Information
    • Research & Development
    • Quality & Safety
  • Therapies
    • Therapeutic areas
      • Rare Diseases
      • Mother and Child Health
      • Critical care and transplantation
      • Transfusion Medicine
    • Business Partners
  • Services
    • Italian partnership
    • Contract manufacturing
    • Technology transfer
    • Biological Safety Center
  • Donors
    • Plasma
  • Pharmacovigilance
kedrion logo
Find in Kedrion


Kedrion-Kamada, Anti-COVID IG development update

Apr 21, 2021 | News > PLASMA & BIOTHERAPIES

Kedrion Biopharma and Kamada are forging ahead with the development of a new Anti-COVID Immunoglobulin therapy derived from the plasma of convalescent patients.

Watch today’s interview by Kamada’s CEO Amir London on LeFontiTV to learn more about the status of the project.



For more information please contact: [email protected]

Kedrion

Kedrion S.p.A. with sole Shareholder
Subject to control and coordination of Kedrion Holding SpA

Sede legale: Loc. Ai Conti snc, Castelvecchio Pascoli, 55051-Barga (LU)

CF – PI Registro delle Imprese della TOSCANA NORD-OVEST N° REA LU – 01779530466
Cap. Soc. i.v. euro 60.453.901,00

HIGHLIGHTS

  • BIOSC for pathogen safety
  • Kedrion Annual Reports

USEFUL INFO

  • Credits
  • Site Map
  • Cookies
  • Terms of Use

Where We Are

© Kedrion 2023 / Kedrion S.p.A

You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.

Kedrion logoLogo Header Menu
    • About us
      • Corporate Structure
      • Annual Report
      • Corporate Social Responsibility
        • Code of Conduct
        • Environment, Health & Safety
        • Supporting our people
        • Support to communities
    • Expertise
      • Activities
      • Medical & Scientific Information
      • Research & Development
      • Quality & Safety
    • Therapies
      • Therapeutic areas
        • Rare Diseases
        • Mother and Child Health
        • Critical care and transplantation
        • Transfusion Medicine
      • Business Partners
    • Services
      • Italian partnership
      • Contract manufacturing
      • Technology transfer
      • Biological Safety Center
    • Donors
      • Plasma
    • Pharmacovigilance
  • News
  • Contact
  • Careers
    • Work with us
    • Privacy Notice
  • Investor Relations
  • Kedrion’s Sites
    • Kedrion S.p.A
    • Kedrion Biopharma GmbH
    • Kedrion Biopharma – Austria
    • Kedrion Biopharma – Portugal
    • Kedrion Biopharma – Poland
    • Kedrion Biopharma – Russia
    • HUMAN Bioplazma Kft
    • Kedrion Biopharma Inc.
    • Kedrion Mexicana S.A.
    • KEDPLASMA USA
    • Kedrion Betaphar
  • Social Network
    • LinkedIn